TY  - JOUR
T1  - The Effects of Halofuginone and Ursodeoxycholic Acid in Prevention of Sclerosing Cholangitis Caused by Scolocidal Agents
TT  - Skolosidal Ajanlardan Kaynaklanan Sklerozan Kolanjitin Önlenmesinde Halofuginon ve Ursodeoksikolik Asidin Etkileri
AU  - Kocakuşak, Ahmet
AU  - Yıldırım, Doğan
AU  - Aktürk, Okan Murat
AU  - Çakır, Mikail
AU  - Sunamak, Oğuzhan
AU  - Hut, Adnan
AU  - Zengin, Abdullah Kağan
AU  - Özcan, Murat
AU  - Akı, Hilal
AU  - Balcı, Huriye
PY  - 2020
DA  - May
Y2  - 2019
DO  - 10.17944/mkutfd.425288
JF  - The Medical Journal of Mustafa Kemal University
JO  - mkutfd
PB  - Hatay Mustafa Kemal Üniversitesi
WT  - DergiPark
SN  - 2149-3103
SP  - 26
EP  - 30
VL  - 11
IS  - 39
LA  - en
AB  - Aim:Biliarysclerosis is a life treatening condition caused by auto-immunity, operativetrauma, toxic agents, cancer and chronic inflammatory conditions. The liver tissue may progress into overt cirrhosisby the progression of fibrotic scar tissue. Halofuginone, which is the active component of theplant alkaloid febrifugine, has been shown to inhibit fibrosis.Material and Method:Fifty rats were randomizedon 5 groups to form a biliary sclerosis model by a scolocidal agent povidoneiodine(PI) injection into the common bile duct with a control group of salineinfusion included. The four PI groups were later treated by halofuginone, ursodeoxycholicacid (UDCA), with both and none. The rats were sacrificed 90 days later for intrahepaticand hilar fibrosis. Laboratory parameters of liver damage and levels ofhydroxypryroline to show collagen degradation were obtained and histologicalexamination of the liver and the common bile duct for fibrotic changes werecarried out.Results:With or without applicationof ursodeoxycholic acid, the halofuginone groups showed significantly lesssclerosis according to histological analysis. In regard to serum analysis of SGOT,SGPT and ALP; there were significantdifferences between “PI only” group and halofuginone groups. GGT was significantlyhigh in “PI only” group. There was not any significant difference between thegroups in regard to bilirubin levels. Hydroxyproline serum levels were highestin “PI only” group, followed by “UDCAonly” group and then halofuginone groups.Conclusion:Halofuginone was effectivein preventing fibrosis as an additional medical therapy to UDCA in an inducedsclerosing cholangitis model in rats.
KW  - Halofuginone
KW  - cirrhosis
KW  - ursodeoxycholic acid
KW  - sclerosing cholangitis
KW  - fibrosis
KW  - scolocidal
N2  - Amaç:Biliyer skleroz,otoimmünite, operatif travma, toksik ajanlar, kanser ve kronik inflamatuvarkoşulların neden olduğu yaşamı tehdit eden durumdur. Karaciğer dokusu, fibrotikskar dokusunun ilerlemesi ile belirgin siroza doğru ilerleyebilir. Alkaloidfebrifugine bitkisinin aktif bileşeni olan halofuginonun, fibrozisi inhibe ettiğigösterilmiştir.Gereç ve Yöntemler:Elli sıçan, bir tanesisalin infüzyonu içeren bir kontrol grubu da içinde olmak üzere beş grubarandomize edilerek, koledoka skolosidal bir ajan olan povidon iyot (PI)enjeksiyonu ile bir biliyer skleroz modeli oluşturuldu. PI grupları (kontrolhariç tüm gruplar) daha sonra ya halofuginon, ya ursodeoksikolik asit (UDCA),ya ikisi beraber, ya da hiçbir madde verilmeyerek 90 gün takip edildi. Takipsonunda sıçanlar, intrahepatik ve hiler fibrozis tespiti için sakrifiye edildi.Karaciğer hasarının laboratuvar parametreleri ve kollajen degradasyonunugöstermek üzere hidroksiprolin düzeyleri serumda çalışıldı. Fibrotikdeğişikliklerin analizi için karaciğer ve koledokun histolojik incelemesiyapıldı.Bulgular:Ursodeoksikolik asitkullanılmış olsun veya olmasın, halofuginon kullanılan grupların histolojikanalizinde diğer gruplara göre istatistiksel açıdan alamlı derecede az sklerozmevcut idi. SGOT, SGPT ve ALP'nin serum analizleri incelendiğinde; "sadecePI kullanılan grup" ve halofuginon grupları arasında anlamlı farklılıklarvardı. GGT sadece PI kullanılan grup için anlamlı derecede yüksekti. Bilirubindüzeyleri açısından gruplar arasında anlamlı fark yoktu. Hidroksiprolin serumdüzeyleri "sadece PI kullanılan grup" için en yüksek olup, bunu sadeceUDCA kulanılan grup ve ardından halofuginon grupları izledi.Sonuç:Halofuginon, sıçanlardaindüklenen bir sklerozan kolanjit modelinde UDCA'ya ek bir tıbbi tedavi olarak karaciğerve safra yollarında fibrozun önlenmesinde etkili olmuştur.
CR  - Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology 2012; 60: 236–48.
CR  - Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013; 382:1587–99.
CR  - MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983; 149: 39–44.
CR  - Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383: 1749–61.
CR  - Penz-Österreicher M, Österreicher CH, Trauner M. Fibrosis in autoimmune and cholestatic liver disease. Best Pract Res Clin Gastroenterol 2011; 25: 245–58.
CR  - Ruemmele P, Hofstaedter F, Gelbmann CM. Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol 2009; 6:287-95.
CR  - Coatney GR, Cooper WC, Culwell WB, White WC, Imboden CA Jr. Studies in human malaria. XXV. Trial of febrifugine, an alkaloid obtained from Dichroa febrifuga lour., against the Chesson strain of Plasmodium vivax. J Natl Malar Soc 1950; 9: 183–6.
CR  - Sundrud MS, Koralov SB, Feuerer M, Calado DP, Kozhaya AE, Rhule-Smith A, et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 2009; 324: 1334–8.
CR  - Keller TL, Zocco D, Sundrud MS, Hendrick M, Edenius M, Yum J, et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol 2012; 8: 311-7.
CR  - Ward A, Brogden RN, Heel RC, Speight TM, Avery GS. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs 1984;27:95-131.
CR  - Saksena S, Tandon RK. Ursodeoxycholic acid in the treatment of liver diseases. Postgraduate Med J 1997; 73: 75-80.
CR  - Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36: 525-531.
CR  - Hohenester S, Oude-Elferink RPJ, Beuers U. Primary biliary cirrhosis. Seminars in Immunopathology. 2009;31(3):283-307.
CR  - Zhen YZ, Li NR, He HW, Zhao SS, Zhang GL, Hao XF, et al. Protective effect of bicyclol against bile duct ligation-induced hepatic fibrosis in rats. World J Gastroenterol 2015; 21: 7155-64.
CR  - Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P, Moreno MG, et al. Curcumin prevents and reverses cirrhosis induced by bile duct obstruction or CCl4 in rats: role of TGF-beta modulation and oxidative stress. Fundam Clin Pharmacol 2008; 22:417–27.
CR  - Pines M, Halevy O. Halofuginone and muscular dystrophy. Histol Histopathol 2011;26: 135-46.
CR  - Cui Z, Crane J, Xie H, Jin X, Zhen G, Li C, et al. Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Ann Rheum Dis 2016; 75: 1714-21.
CR  - Pines M, Knopov V, Genina O, Lavelin I, Nagler A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J Hepatol 1997; 27: 391-8.
CR  - Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Avni Y, Pines M. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001; 33: 379-86.
CR  - Liang J, Zhang B, Shen RW, Liu J-B, Gao M-h, Li Y, et al. Preventive Effect of Halofuginone on Concanavalin A-Induced Liver Fibrosis. PLoS ONE 2013; 8: e82232. doi:10.1371/journal.pone.0082232.
CR  - Yavas G, Calik M, Calik G, Yavas C, Ata O, Esme H. The effect of Halofuginone in the amelioration of radiation induced-lung fibrosis. Med Hypotheses 2013; 80: 357-9.
CR  - Choi ET, Callow AD, Sehgal NL, Brown DM, Ryan US. Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intimal hyperplasia. Arch Surg 1995; 130:257-61.
CR  - Nagler A, Miao HQ, Aingorn H, Pines M, Genina O, Vlodavsky I. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler Thromb Vasc Biol 1997; 17: 194-202.
UR  - https://doi.org/10.17944/mkutfd.425288
L1  - https://dergipark.org.tr/tr/download/article-file/1110907
ER  -